Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Jiangsu Hengrui Pharmaceuticals (1276.HK)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date Stock Price (HK$) Price Target (HK$) Rating
2022-04-15NaN-No Rating
2025-07-0255.4076.00Buy
2025-07-1074.5587.30Buy

Disclosures

  • UBS has acted as manager/co-manager in the underwriting or placement of securities of this company/entity or one of its affiliates within the past 12 months.
  • Within the past 12 months, UBS has received compensation for investment banking services from this company/entity or one of its affiliates.
  • UBS expects to receive or intend to seek compensation for investment banking services from this company/entity within the next three months.
  • Market capitalisation is calculated by multiplying the current share price by the sum of A and H shares.
  • UBS holds a long or short position of 0.5% or more of the listed shares of this company.
Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.